Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 4;48(1):142.
doi: 10.1186/s13052-022-01335-1.

Protection against MIS-C outweighs the risk of myocarditis after Covid-19 vaccination in children

Marcello Mariani  1   2 , Roberta Caorsi  3 , Alessandro Consolaro  4   3 , Giacomo Brisca  5 , Camilla Sticchi  6 , Marco Gattorno  3 , Elio Castagnola  7 , Angelo Ravelli  4   8
Affiliations

Protection against MIS-C outweighs the risk of myocarditis after Covid-19 vaccination in children

Marcello Mariani et al. Ital J Pediatr. .

Abstract

From March 2020 to July 2022, in Liguria region (North-West Italy) incidence of MIS-C among pediatric patients infected by SARS-CoV-2 was 38.7/100.000, which is higher than that of myocarditis after COVID-19 vaccination. In our opinion severity of MIS-C-related cardiac disease outweigh the risk of myocarditis after COVID-19 vaccine.

Keywords: BNT162b2; Children; Vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors have no other relevant financial or non-financial interests to disclose.

Figures

Fig. 1
Fig. 1
Incidence comparison between MIS-C indicence in pediatric population from Liguria Region, Italy in 2020-2022. Data are expressed as cases * 100.000 inhabitants under 19 years of age
See this image and copyright information in PMC

References

    1. Dagan N, Barda N, Balicer RD. Adverse effects after BNT162b2 vaccine and SARS-CoV-2 infection, according to age and sex. N Engl J Med. 2021;2115045. 10.1056/nejmc2115045. - PMC - PubMed
    1. Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory committee on immunization practices — United States, June 2021. MMWR Morb Mortal Wkly Rep. 2021;70:977–982. doi: 10.15585/MMWR.MM7027E2. - DOI - PMC - PubMed
    1. Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. N Engl J Med. 2021:1–10. 10.1056/nejmoa2109730. - PMC - PubMed
    1. Frenck RW, Klein NP, Kitchin N, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021;385:239–250. doi: 10.1056/nejmoa2107456. - DOI - PMC - PubMed
    1. Walter EB, Talaat KR, Sabharwal C, et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. N Engl J Med. 2021:1–12. 10.1056/NEJMoa2116298. - PMC - PubMed

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources